Skip to content
Screener

Pacific Biosciences of California PACB Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$39.0MMiss by $3.9M
EPS-$0.14Miss by $0.01
Revenue estimate$42.9M
EPS estimate-$0.13
“I am honored to have the opportunity to lead PacBio at such an exciting time in the company's evolution, especially as we continue our pivot into further supporting the clinical markets and developing AI-related product solutions and clinically relevant databases. PacBio has built an industry-leading technology platform, an incredibly talented team, and a passionate customer community that is driving scientific and clinically important discoveries around the world. I am grateful to Christian for his leadership, mentorship, and partnership over the past several years. His vision and dedication have positioned PacBio for a tremendous future, and I look forward to building on that strong foundation.”
Mark Van Oene

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$43.8M
EPS estimate-$0.13

Financials

Q2 2026

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$416.51M+12.7%
Enterprise value$415.7M+13.7%
P/S2.6×+0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Current ratio4.9×-2.0×

Segments

By geography

See full
Americas$17.6M-0.4%
Europe, Middle East and Africa$14.4M+52.4%
Asia-Pacific$7.0M-44.8%

By product

See full
Consumable revenue$20.1M+6.2%
Instrument revenue$12.8M-9.3%
Service and other revenue$6.1M-9.4%

By segment

See full
Reportable Segment$39.0M-1.9%

FAQ

When did Pacific Biosciences of California report Q2 2026 earnings?
Pacific Biosciences of California (PACB) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Pacific Biosciences of California's Q2 2026 revenue and EPS?
Pacific Biosciences of California reported revenue of $39.0M and eps of $-0.14 for Q2 2026.
Did Pacific Biosciences of California beat estimates in Q2 2026?
Revenue missed the consensus estimate of $42.9M by $3.9M. EPS missed the consensus estimate of $-0.13 by $0.01.
How did Pacific Biosciences of California's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.9% from $39.8M a year earlier and eps declined 7.7% from $-0.13.
Where can I find Pacific Biosciences of California's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001299130-26-000117) and the 10-Q periodic report (0001299130-26-000122) directly on SEC EDGAR. The filing index links above go to sec.gov.